semaglutide alcohol use disorder study Semaglutide treats alcohol use disorder with obesity

Medscape | Once weekly semaglutide injections reduced alcohol consumption in patients with alcohol use disorder and comorbid obesity. Results of the...

23.76

★★★★☆4.8 (126)

GLP-1 medications: The next big thing in alcohol use disorder treatment? – Recovery Research Institute

20.85

★★★★★4.9 (98)

For decades, addiction was framed primarily as a problem of behavior But biology tells a more complicated story The same medications now transforming obesity medicine may also be influencing reward pathways, cravings,

21.73

★★★★★5.0 (157)

🚨 New study published in The Lancet 💉 Weekly semaglutide 2.4 mg showed a significant reduction in alcohol consumption among patients with obesity and alcohol use disorder. 📊 This is the first

21.62

★★★★★4.7 (84)

I'm grateful to be quoted in Forbes discussing a new Lancet study looking at semaglutide and alcohol use disorder in people with obesity. The study found that adults with alcohol use disorder

27.49

★★★★★4.9 (203)

Ozempic just reduced heavy drinking by 41% in a randomized controlled trial. Let that sink in. A study published this week in The Lancet — the SEMALCO trial — enrolled 108 patients

22.83

★★★★★5.0 (176)

A new study in The Lancet is raising big questions about the future of alcohol use disorder treatment. Researchers tested once-weekly semaglutide, the drug sold as Wegovy, in people with both obesity

20.46

★★★★★4.8 (132)